The role of FOXP3 in non-small cell lung cancer and its therapeutic potentials

Jia Peng; Shucai Yang; Calvin S H Ng; George G Chen

doi:10.1016/j.pharmthera.2022.108333

The role of FOXP3 in non-small cell lung cancer and its therapeutic potentials

Pharmacol Ther. 2023 Jan:241:108333. doi: 10.1016/j.pharmthera.2022.108333. Epub 2022 Dec 14.

Authors

Jia Peng¹, Shucai Yang², Calvin S H Ng³, George G Chen⁴

Affiliations

¹ Department of Surgery, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China.
² Pingshan District People's Hospital of Shenzhen, Shenzhen, China.
³ Department of Surgery, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China. Electronic address: calvinng@surgery.cuhk.edu.hk.
⁴ Department of Surgery, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China; Department of Otorhinolaryngology, Head and Neck Surgery, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China. Electronic address: gchen@cuhk.edu.hk.

PMID: 36528259
DOI: 10.1016/j.pharmthera.2022.108333

Abstract

Although in the last few decades we have witnessed the rapid development of treatments for non-small cell lung cancer (NSCLC), it still remains the leading cause of cancer-related death. Increasing efforts have been devoted to exploring potential biomarkers and molecular targets for NSCLC. Foxp3, a transcription factor that was discovered as a master regulator of regulatory T cells (Tregs), has been found to express abnormally in tumoral cells including lung cancer cells. In recent years, increasing evidence have surfaced, revealing the carcinogenic effect of FOXP3 in lung cancer. In this review, we analyzed and summarized the function of FOXP3, its regulation and therapeutic potentials in NSCLC, with a hope to facilitate the development of novel treatments for NSCLC.

Keywords: FOXP3; NSCLC; Oncogene; Therapeutic target.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Carcinoma, Non-Small-Cell Lung* / drug therapy
Carcinoma, Non-Small-Cell Lung* / metabolism
Forkhead Transcription Factors
Humans
Lung / metabolism
Lung Neoplasms* / drug therapy
Lung Neoplasms* / metabolism
T-Lymphocytes, Regulatory

Substances

Forkhead Transcription Factors
FOXP3 protein, human